Amgen announced a $600 million investment to expand its headquarters in Thousand Oaks, California, establishing a new state-of-the-art research and development center. Construction is scheduled to commence this quarter, with the facility designed to support next-generation drug discovery through advanced automation and digital capabilities. This expansion complements recent manufacturing facility investments in Ohio and North Carolina and aligns with favorable US tax policies that incentivize domestic life sciences growth. Amgen’s move underscores continued commitment to US biotechnology infrastructure amid evolving trade policies and import tariffs.